In the top alliance by deal value, Zealand Pharma entered into a global collaboration and license agreement with Roche to develop petrelintide, Zealand’s amylin analog as a foundational therapy for weight management, while rapidly expanding into related indications. The total value of the partnership could reach $5.3bn.
Deals In Depth: March 2025
Eight $1bn+ alliances were penned in March, and five exceeded $2bn.
